<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "journalpublishing.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="2.0" xml:lang="en" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Public Health Surveill</journal-id><journal-id journal-id-type="publisher-id">publichealth</journal-id><journal-id journal-id-type="index">9</journal-id><journal-title>JMIR Public Health and Surveillance</journal-title><abbrev-journal-title>JMIR Public Health Surveill</abbrev-journal-title><issn pub-type="epub">2369-2960</issn><publisher><publisher-name>JMIR Publications</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">v12i1e82208</article-id><article-id pub-id-type="doi">10.2196/82208</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Molecular Transmission Clustering and Pretreatment Drug Resistance Among Men Infected With HIV-1 Who Have Sex With Men in Baotou, China: A Cross-Sectional Subgroup Analysis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Li</surname><given-names>Hanping</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Liu</surname><given-names>Yu</given-names></name><degrees>MPH</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Yang</surname><given-names>Hong</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names>Jiao</given-names></name><degrees>MPH</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names>Ziwei</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bai</surname><given-names>Baobao</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names>Yongjian</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jia</surname><given-names>Lei</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Han</surname><given-names>Jingwan</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Bohan</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names>Xiaolin</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names>Xiangchun</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Li</surname><given-names>Lin</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><institution>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences</institution><addr-line>20 Dongda Street, Fengtai District</addr-line><addr-line>Beijing</addr-line><country>China</country></aff><aff id="aff2"><institution>School of Public Health, Inner Mongolia Medical University</institution><addr-line>Hohhot</addr-line><country>China</country></aff><aff id="aff3"><institution>Department of HIV/AIDS Control and Prevention, Inner Mongolia Autonomous Region Center for Disease Control and Prevention</institution><addr-line>Hohhot</addr-line><country>China</country></aff><aff id="aff4"><institution>School of Public Health, Hebei Medical University</institution><addr-line>Shijiazhuang</addr-line><country>China</country></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Brini</surname><given-names>Stefano</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name name-style="western"><surname>Zhao</surname><given-names>Jinkou (Button)</given-names></name></contrib><contrib contrib-type="reviewer"><name name-style="western"><surname>Li</surname><given-names>Mu</given-names></name></contrib></contrib-group><author-notes><corresp>Correspondence to Lin Li, PhD, State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, 20 Dongda Street, Fengtai District, Beijing, 100071, China, +86-13460359811; <email>dearwood@sina.com</email></corresp><fn fn-type="equal" id="equal-contrib1"><label>*</label><p>these authors contributed equally</p></fn></author-notes><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>6</day><month>11</month><year>2026</year></pub-date><volume>12</volume><elocation-id>e82208</elocation-id><history><date date-type="received"><day>17</day><month>08</month><year>2025</year></date><date date-type="rev-recd"><day>20</day><month>05</month><year>2026</year></date><date date-type="accepted"><day>21</day><month>05</month><year>2026</year></date></history><copyright-statement>&#x00A9; Hanping Li, Yu Liu, Hong Yang, Jiao Wu, Ziwei Liu, Baobao Bai, Yongjian Liu, Lei Jia, Jingwan Han, Bohan Zhang, Xiaolin Wang, Xiangchun Li, Lin Li. Originally published in JMIR Public Health and Surveillance (<ext-link ext-link-type="uri" xlink:href="https://publichealth.jmir.org">https://publichealth.jmir.org</ext-link>), 6.11.2026. </copyright-statement><copyright-year>2026</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="https://publichealth.jmir.org">https://publichealth.jmir.org</ext-link>, as well as this copyright and license information must be included.</p></license><self-uri xlink:type="simple" xlink:href="https://publichealth.jmir.org/2026/1/e82208"/><abstract><sec><title>Background</title><p>In the Inner Mongolia Autonomous Region, men who have sex with men (MSM) have become a high-risk group for HIV transmission due to their complex, secretive sexual relationships, posing challenges to HIV-1 prevention.</p></sec><sec><title>Objective</title><p>We analyzed factors associated with molecular transmission clustering and pretreatment drug resistance (PDR) among newly reported HIV-1&#x2013;infected MSM in Baotou, China, and to provide locally relevant evidence for targeted public health interventions.</p></sec><sec sec-type="methods"><title>Methods</title><p>We conducted a subgroup cross-sectional molecular epidemiological analysis of all newly reported HIV-1 cases attributed to homosexual transmission in Baotou between January 2022 and December 2024. The sample comprised 213 treatment-na&#x00EF;ve MSM, from whom plasma samples were obtained. A 1.3-kb fragment of the HIV-1 pol gene was amplified and sequenced using next-generation sequencing. Inclusion criteria were a newly reported HIV-1 infection, no antiretroviral therapy at the time of this writing, and self-reported same-sex sexual behavior. Primary outcomes were clustering in a genetic distance&#x2013;based molecular transmission network and the presence of PDR according to the Stanford HIV Drug Resistance Database.</p></sec><sec sec-type="results"><title>Results</title><p>In total, 176 pol gene sequences were successfully obtained, with circulating recombinant form (CRF)&#x2013;07_BC being the most prevalent subtype, accounting for 56.82% of the total sequences. The molecular transmission network was constructed using a pairwise genetic distance of 1.30%, with 52 of 176 (29.55%) sequences forming 19 clusters within the network. The network exhibited significant assortative mixing by age (ra=0.41; <italic>P</italic>=.001), marital status (ra=0.408; <italic>P</italic>=.002), and educational attainment (ra=0.385; <italic>P</italic>=.001), rather than random mixing. Multivariate logistic regression analysis revealed that CRF07_BC subtype&#x2013;infected individuals had a significantly higher risk of clustering (AOR 4.98; 95% CI 1.92&#x2010;12.94; <italic>P</italic>&#x003C;.01). Compared to never-married individuals, divorced or widowed individuals were less likely to have clustered cases (AOR 0.27; 95% CI 0.08&#x2010;0.92; <italic>P</italic>&#x003C;.05). The prevalence of PDR was 6.57% (n=14). Nonnucleoside reverse transcriptase inhibitor resistance was the most common (n=8, 3.76%), followed by protease inhibitor resistance (n=5, 2.35%), and nucleoside reverse transcriptase inhibitor resistance (n=3, 1.14%). Drug-resistant strains were more frequently detected among individuals infected with the CRF07_BC subtype (<italic>&#x03C7;</italic><sup>2</sup><sub>8</sub>=90.44; <italic>P&#x003C;</italic>.001).</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Unlike previous studies primarily focused on high-burden southeastern coastal regions of China, we investigated the molecular transmission characteristics of HIV-1 among MSM in the Inner Mongolia Autonomous Region. Our findings demonstrate that transmission clustering and drug resistance patterns previously observed are also present in northern border areas. This study integrated HIV-1 molecular transmission network analysis with next-generation sequencing technologies to identify key populations involved in local HIV transmission, thereby supporting targeted public health interventions. In addition, surveillance of PDR among high-risk populations may facilitate the development of evidence-based antiretroviral treatment strategies and improve the efficient allocation of limited health care resources.</p></sec></abstract><kwd-group><kwd>HIV&#x2010;1</kwd><kwd>phylogenetic analysis</kwd><kwd>genetic clustering</kwd><kwd>molecular transmission network</kwd><kwd>pretreatment drug resistance</kwd></kwd-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>AIDS is a chronic infectious disease caused by HIV. AIDS continues to pose substantial challenges to public health, demographic stability, and socioeconomic development worldwide. The US Centers for Disease Control and Prevention (CDC) reports that in 2023, over 80% of those diagnosed with HIV were men, with 66% of those cases linked to men who have sex with men (MSM) [<xref ref-type="bibr" rid="ref1">1</xref>]. A nationwide study showed that in some regions of China, 21.4%-23.4% of new AIDS cases were related to HIV transmission among MSM [<xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref3">3</xref>]. The HIV-1 prevalence rate among MSM in China rose from 5.7% in 2010 to 23.0% in 2019 [<xref ref-type="bibr" rid="ref4">4</xref>]. As a relatively small group with complex social relationships, some MSM may simultaneously engage in both receptive and insertive sexual behavior, which accelerates HIV transmission. Therefore, given the critical role that MSM play in HIV-1 prevention and management efforts, studying their molecular epidemiological characteristics is of vital importance.</p><p>Due to underreporting in MSM, the actual proportion of infections transmitted through MSM may be underestimated. Socioepidemiological investigations can provide some information on HIV-1 transmission patterns, but the secrecy of MSM sexual behaviors limits the reliability of the information obtained on HIV transmission [<xref ref-type="bibr" rid="ref5">5</xref>]. Interventions targeting individual high-risk behaviors have had limited effectiveness in eliminating HIV/AIDS. Consequently, research focus has shifted to the role of networks in HIV transmission, including sexual transmission networks, social networks, and molecular transmission networks [<xref ref-type="bibr" rid="ref6">6</xref>]. With continuous advances in genomic sequencing technologies and the ongoing accumulation of data on HIV drug resistance, researchers have increasingly focused on molecular transmission networks constructed from viral sequence data. These networks offer unique advantages. They can trace viral transmission pathways and identify clusters of drug-resistant strains, pinpoint risk factors for HIV transmission, and reveal potential transmission routes within transmission chains, thereby facilitating targeted interventions. The use of molecular transmission networks to identify clusters of high-risk individuals supplements the incomplete information obtained solely through studying social and sexual behavior patterns among people living with HIV [<xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref8">8</xref>]. By using these insights, public health measures can more effectively curb viral transmission and reduce infection rates [<xref ref-type="bibr" rid="ref9">9</xref>-<xref ref-type="bibr" rid="ref11">11</xref>].</p><p>Antiretroviral therapy (ART) remains the best treatment option for HIV/AIDS [<xref ref-type="bibr" rid="ref12">12</xref>]. It effectively suppresses viral replication, reduces mortality, and improves patients&#x2019; quality of life [<xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref>]. With the expansion of ART coverage, most patients achieve viral suppression and maintain a certain level of immune function following antiviral treatment. However, with the widespread use of antiviral drugs, the virus continues to undergo genetic mutations under selective pressure, leading to reduced drug sensitivity and the development of drug resistance, which in turn results in treatment failure. Some drug-resistant mutant strains may spread from treatment-failed patients to untreated individuals, and certain mutant strains with transmission advantages may spread widely in the population, leading to increased proportions of transmission-associated drug resistance and pretreatment drug resistance (PDR) [<xref ref-type="bibr" rid="ref15">15</xref>-<xref ref-type="bibr" rid="ref17">17</xref>]. PDR refers to drug resistance detected in individuals with no prior history of ART exposure. PDR may reduce the efficacy of ART, increase mortality, and lead to secondary transmission of HIV [<xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref18">18</xref>]. Therefore, assessing PDR levels helps to better understand the current status of HIV-1 drug resistance in specific regions and provides a foundation for formulating alternative treatment strategies.</p><p>In China, individual ART regimens are primarily determined by national standard first-line and second-line treatment strategies [<xref ref-type="bibr" rid="ref19">19</xref>], and people living with HIV should initiate antiviral treatment as early as possible, within 30 days of diagnosis. Typically, individual HIV genotypic resistance testing is required before starting ART. Failure to identify drug-resistant strains in a timely manner may facilitate onward viral transmission. Since 2011, the prevalence of PDR in China has shown an upward trend [<xref ref-type="bibr" rid="ref20">20</xref>]. Data from a multicenter observational study indicate that the overall prevalence of PDR in China was 7.40% in 2022 [<xref ref-type="bibr" rid="ref19">19</xref>]. Previous studies have shown that while several common mutations account for the transmission of most subtypes and cases of high-level resistance, the prevalence of PDR among HIV-1-infected MSM varies geographically. For example, the prevalence of PDR was 12.72% in Guiyang [<xref ref-type="bibr" rid="ref21">21</xref>], and in Chongqing it was 5.60% [<xref ref-type="bibr" rid="ref22">22</xref>].</p><p>Inner Mongolia Autonomous Region is located in the northern frontier of China, and Baotou is situated in the central-western part of the region. Between 2022 and 2024, 99.36% of newly reported cases in Baotou were sexually transmitted infections, with MSM accounting for 65.14% of these cases. Although homosexual transmission is predominant in the city, research on the transmission patterns among MSM remains limited. Therefore, the primary objectives of this study were (1) to characterize the HIV-1 molecular transmission network and identify factors associated with phylogenetic clustering among newly reported MSM in Baotou; (2) to assess the prevalence and patterns of PDR in this population; and (3) to provide locally relevant evidence for targeted public health interventions. An analysis of representative cities is not only crucial for refining and evaluating the effectiveness of HIV-1 prevention and control strategies in the Inner Mongolia Autonomous Region but also provides valuable insights for other cities. This approach facilitates a deeper understanding of HIV-1 transmission risks at the local level and enables the rational distribution of limited public health resources to achieve targeted interventions against HIV/AIDS.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-2"><title>Study Design</title><p>This study is a subgroup analysis derived from a broader HIV-1 molecular surveillance project conducted in Baotou, Inner Mongolia Autonomous Region, between January 2022 and December 2024 [<xref ref-type="bibr" rid="ref23">23</xref>]. This subgroup analysis was preplanned to address the research questions specific to the MSM population, which accounts for the highest proportion of newly reported HIV-1 cases in the region.</p></sec><sec id="s2-3"><title>Inclusion and Exclusion Criteria</title><p>Inclusion criteria were (1) newly reported HIV-1 infection, (2) no prior exposure to ART, and (3) men who self-reported having sex with men. Exclusion criteria were (1) individuals with a prior history of ART exposure, (2) individuals who declined to provide written informed consent or who withdrew consent during the study period, and (3) cases where plasma samples were insufficient in volume (&#x003C;200 &#x03BC;L).</p></sec><sec id="s2-4"><title>Participant Characteristics</title><p>A total of 213 ART-na&#x00EF;ve MSM were enrolled in this study. Their median age was 33 (IQR 26&#x2010;45) years. Additional demographic and clinical characteristics of the 176 participants with successfully sequenced samples are summarized in <xref ref-type="table" rid="table1">Table 1</xref>.</p><table-wrap id="t1" position="float"><label>Table 1.</label><caption><p>Demographics and HIV-1 subtypes in men who have sex with men (MSM)&#x2013;infected individuals.</p></caption><table id="table1" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Variables</td><td align="left" valign="bottom">Participants (N=176)</td><td align="left" valign="bottom" colspan="3">Subtype</td><td align="left" valign="bottom">HIV-1 subtype B (n=6)</td><td align="left" valign="bottom">Other<sup><xref ref-type="table-fn" rid="table1fn1">a</xref></sup><break/>(n=9)</td><td align="left" valign="bottom"><italic>P</italic> value<italic><sup><xref ref-type="table-fn" rid="table1fn2">b</xref></sup></italic></td></tr><tr><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top">CRF<sup><xref ref-type="table-fn" rid="table1fn3">c</xref></sup>01_AE<break/>(n=51)</td><td align="left" valign="top">CRF07_BC<break/>(n=100)</td><td align="left" valign="top">CRF55_01B<break/>(n=10)</td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr></thead><tbody><tr><td align="left" valign="top">Reported (year), n (%)</td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top">.12</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>2022</td><td align="left" valign="top">63 (35.80)</td><td align="left" valign="top">19 (30.16)</td><td align="left" valign="top">35 (55.56)</td><td align="left" valign="top">4 (6.35)</td><td align="left" valign="top">2 (3.17)</td><td align="left" valign="top">3 (4.76)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>2023</td><td align="left" valign="top">64 (36.36)</td><td align="left" valign="top">14 (21.88)</td><td align="left" valign="top">39 (60.94)</td><td align="left" valign="top">6 (9.38)</td><td align="left" valign="top">2 (3.13)</td><td align="left" valign="top">3 (4.69)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>2024</td><td align="left" valign="top">49 (27.84)</td><td align="left" valign="top">18 (36.73)</td><td align="left" valign="top">26 (53.06)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">2 (4.08)</td><td align="left" valign="top">3 (6.12)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Ethnicity, n (%)</td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top">.56</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Han Chinese</td><td align="left" valign="top">162 (92.05)</td><td align="left" valign="top">47 (29.01)</td><td align="left" valign="top">91 (56.17)</td><td align="left" valign="top">9 (5.56)</td><td align="left" valign="top">6 (3.7)</td><td align="left" valign="top">9 (5.56)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Mongol</td><td align="left" valign="top">12 (6.82)</td><td align="left" valign="top">4 (33.33)</td><td align="left" valign="top">8 (66.67)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Hui</td><td align="left" valign="top">2 (1.14)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">1 (50.00)</td><td align="left" valign="top">1 (50.00)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Age (years), n (%)</td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top">.49</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>&#x003C;30</td><td align="left" valign="top">59 (33.52)</td><td align="left" valign="top">18 (30.51)</td><td align="left" valign="top">31 (52.54)</td><td align="left" valign="top">4 (6.78)</td><td align="left" valign="top">3 (5.08)</td><td align="left" valign="top">3 (5.08)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>30&#x2010;50</td><td align="left" valign="top">91 (51.70)</td><td align="left" valign="top">26 (28.57)</td><td align="left" valign="top">53 (58.24)</td><td align="left" valign="top">5 (5.49)</td><td align="left" valign="top">2 (2.20)</td><td align="left" valign="top">5 (5.49)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>&#x003E;50</td><td align="left" valign="top">26 (14.77)</td><td align="left" valign="top">7 (26.92)</td><td align="left" valign="top">16 (61.54)</td><td align="left" valign="top">1 (3.85)</td><td align="left" valign="top">1 (3.85)</td><td align="left" valign="top">1 (3.85)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Marital status, n (%)</td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top">.05</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Never married</td><td align="left" valign="top">117 (66.48)</td><td align="left" valign="top">35 (29.91)</td><td align="left" valign="top">65 (55.56)</td><td align="left" valign="top">7(5.98)</td><td align="left" valign="top">5 (4.27)</td><td align="left" valign="top">5 (4.27)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Married</td><td align="left" valign="top">34 (19.32)</td><td align="left" valign="top">7 (20.59)</td><td align="left" valign="top">22 (64.71)</td><td align="left" valign="top">3 (8.82)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">2 (5.88)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Divorced/widowed</td><td align="left" valign="top">25 (14.20)</td><td align="left" valign="top">9 (36.00)</td><td align="left" valign="top">13 (52.00)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">1 (4.00)</td><td align="left" valign="top">2 (8.00)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Education level, n (%)</td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top">.07</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Primary school and illiteracy</td><td align="left" valign="top">10 (5.68)</td><td align="left" valign="top">6 (60.00)</td><td align="left" valign="top">4 (40.00)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Junior middle school</td><td align="left" valign="top">26 (14.77)</td><td align="left" valign="top">10 (38.46)</td><td align="left" valign="top">11 (42.31)</td><td align="left" valign="top">1 (3.85)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">4 (15.38)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Senior middle school and above</td><td align="left" valign="top">140 (79.55)</td><td align="left" valign="top">35 (25.00)</td><td align="left" valign="top">85 (60.71)</td><td align="left" valign="top">6 (4.29)</td><td align="left" valign="top">9 (6.43)</td><td align="left" valign="top">5 (3.57)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">CD4+<sup><xref ref-type="table-fn" rid="table1fn4">d</xref></sup> T lymphocytes, n (%)</td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top">.04</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>&#x003C;200</td><td align="left" valign="top">43 (24.43)</td><td align="left" valign="top">15 (34.88)</td><td align="left" valign="top">19 (44.19)</td><td align="left" valign="top">6 (13.95)</td><td align="left" valign="top">2 (4.65)</td><td align="left" valign="top">1 (2.33)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>200&#x2010;500</td><td align="left" valign="top">91 (51.70)</td><td align="left" valign="top">24 (26.37)</td><td align="left" valign="top">55 (60.44)</td><td align="left" valign="top">3 (3.30)</td><td align="left" valign="top">2 (2.20)</td><td align="left" valign="top">7 (7.69)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x2003;&#x003E;</named-content>500</td><td align="left" valign="top">42 (23.86)</td><td align="left" valign="top">12 (28.57)</td><td align="left" valign="top">26 (61.90)</td><td align="left" valign="top">1 (2.38)</td><td align="left" valign="top">2 (4.76)</td><td align="left" valign="top">1 (2.38)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Registered residence, n (%)</td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top">.51</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Baotou</td><td align="left" valign="top">155 (88.07)</td><td align="left" valign="top">46 (29.68)</td><td align="left" valign="top">86 (55.48)</td><td align="left" valign="top">10 (6.45)</td><td align="left" valign="top">5 (3.23)</td><td align="left" valign="top">8 (5.16)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Other regions in the Inner Mongolia Autonomous Region</td><td align="left" valign="top">5 (2.84)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">4 (80.00)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">1 (20.00)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Other provinces</td><td align="left" valign="top">16 (9.09)</td><td align="left" valign="top">5 (31.25)</td><td align="left" valign="top">10 (62.5)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top">1 (6.25)</td><td align="left" valign="top">0 (0)</td><td align="left" valign="top"/></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><p><sup>a</sup>Other includes CRF67_01B subtype (n=3), CRF59_01B subtype (n=1), CRF08_BC subtype (n=1) and unique recombination form (n=4).</p></fn><fn id="table1fn2"><p><sup>b</sup>Corrected chi-square test was used for reporting year and Fisher exact probability method was used for the remaining variables.</p></fn><fn id="table1fn3"><p><sup>c</sup>CRF: circulating recombinant form.</p></fn><fn id="table1fn4"><p><sup>d</sup>CD4+: cluster of differentiation 4.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-5"><title>Sampling Procedure</title><p>From January 2022 to December 2024, all newly reported cases of HIV-1 infection among MSM in Baotou were continuously recruited through the local CDC. Blood samples were collected after confirmation of infection and prior to initiation of ART. Plasma samples were separated and stored at &#x2212;80 &#x00B0;C immediately after collection. This continuous enrollment approach resulted in a sampling coverage rate of 91.42% (n=213) for all newly reported MSM in the city during the study period.</p></sec><sec id="s2-6"><title>Sample Size Determination</title><p>The sample size was determined by the total number of eligible newly diagnosed HIV-1 cases among MSM in Baotou during the study period.</p></sec><sec id="s2-7"><title>Measures and Covariates</title><p>Demographic variables were obtained from the National Center for AIDS/Sexually Transmitted Disease Control and Prevention (NCAIDS) information system and included age, ethnicity, marital status, educational level, and registered residence. Clinical variables included cluster of differentiation 4 (CD4+) T cell count at diagnosis. HIV-1 sequence analysis was used to determine viral subtype, identify molecular transmission clustering status (clustered or nonclustered based on genetic distance thresholds), and detect PDR-associated mutations.</p></sec><sec id="s2-8"><title>Data Collection and Sources of Secondary Data</title><p>Demographic and epidemiological data were obtained from the NCAIDS information system. Laboratory data, including HIV-1 pol gene sequences, were generated using the Illumina next-generation sequencing (NGS) platform.</p></sec><sec id="s2-9"><title>HIV-1 Nucleic Acid Extraction, Polymerase Chain Reaction Amplification, and Sequencing</title><p>Viral DNA/RNA was extracted using the TGuide S96 Magnetic Bead Method Viral DNA/RNA Extraction Kit (GDP804; TIANGEN Biotech [Beijing] Co, Ltd) according to the manufacturer&#x2019;s instructions. To study the HIV-1 pol gene region, particularly the first 226 codons within the protease (PR) and reverse transcriptase (RT) regions, triple fragment analysis was performed using one-step RT-polymerase chain reaction (PCR; Takara; RR055A) and nested PCR (Takara; RR901A). Amplification primers and conditions have been previously reported [<xref ref-type="bibr" rid="ref24">24</xref>]. Electrophoresis (1% agarose gel) confirmed amplicons from PCR-positive specimens. The library was constructed using segmented labeled amplicons, labeled with unique barcode sequences, and mixed according to the results of DNA quantification to ensure that the DNA input of individual samples was &#x2265;50 ng and the total library amount was &#x2265;150 ng. The prepared libraries were sent to the sequencing company to be analyzed by second-generation sequencing using the Illumina High-Throughput Sequencing Platform after passing the quality test by connecting the P5/P7 sequencing connectors at both ends of the DNA fragments.</p></sec><sec id="s2-10"><title>Sequence Processing and HIV-1 Subtyping</title><p>The second-generation sequencing data in FASTA format provided by the sequencing company were preprocessed under a Linux environment by Mothur software (Patrick D Schloss) for quality control to remove low-quality sequences and mixed sequences. Batch processing in Mothur was performed to generate consensus sequences using a quality-score cutoff of 20. Quality control was performed by the HIV database, excluding sequences with &#x003E;5% mixed bases and those containing stop codons [<xref ref-type="bibr" rid="ref25">25</xref>]. The obtained sequence fragments were calibrated and assembled using Sequencer (v5.4.5; GeneCodes). After preliminary processing, the sequences were manually aligned and edited in BioEdit (v7.7.1; Tom Hall, Ibis Biosciences) and compared with reference sequences in the HIV database at Los Alamos National Laboratory. Phylogenetic analysis was subsequently performed in MEGA (v6.0; Koichiro Tamura, Glen Stecher, Daniel Peterson, Alan Filipski, and Sudhir Kumar) using the neighbor-joining method. For circulating recombinant form (CRF), clustering analysis was first conducted with established international reference strains, and additional validation was performed using the COMET (Daniel Struck) online tool [<xref ref-type="bibr" rid="ref26">26</xref>]. Sequences not clustered with known reference strains were classified as unique recombination forms (URFs) and further analyzed for recombination patterns using the RIP (Siepel AC, Halpern AL, Macken C, Korber BT) [<xref ref-type="bibr" rid="ref27">27</xref>] and jpHMM (Anne-Kathrin Schultz) [<xref ref-type="bibr" rid="ref28">28</xref>] online tools.</p></sec><sec id="s2-11"><title>HIV Molecular Transmission Network Analysis</title><p>To analyze the characteristics of HIV-1 transmission among MSM in Baotou, a molecular network was constructed using collected pol gene sequence data. First, pairwise genetic distances between aligned sequences were calculated using HyPhy (v2.2.4; Sergei L Kosakovsky Pond). Nodes were connected when the pairwise genetic distance between their corresponding sequences fell below the predefined threshold. To more reliably identify infected individuals with potential transmission links within the molecular network, an optimal threshold was selected by maximizing the number of clusters, thereby avoiding network fragmentation or excessive merging. Consequently, sequence pairs with genetic distances &#x003C;1.30% were used to construct the molecular transmission network. Finally, the network was visualized using Cytoscape (v3.5.1; Cytoscape Consortium). The assortativity coefficient (ra) is an important measure of network assortativity, with values ranging from &#x2212;1 to 1 [<xref ref-type="bibr" rid="ref29">29</xref>]. A value close to 1 indicates that the network exhibits high assortativity, meaning similar nodes are more likely to connect with each other. A value close to &#x2212;1 indicates that the network exhibits high disassortativity, meaning nodes of different types are more likely to connect with each other. A value close to 0 indicates that the network connections are random.</p></sec><sec id="s2-12"><title>Drug Resistance Analysis</title><p>According to the National Technical Specifications for AIDS Testing, as outlined by the Chinese Center for Disease Control and Prevention, the sequenced data were forwarded to the HIV Drug Resistance Database of Stanford University [<xref ref-type="bibr" rid="ref30">30</xref>]. Specifically, the HIV database program&#x2019;s sequence analysis online feature was used to assess the genotypic drug resistance mutations and resistance levels in HIV-1-infected MSM. The clinical significance of drug resistance, encompassing protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), and nonnucleoside reverse transcriptase inhibitors (NNRTIs), is categorized into 5 distinct levels for each antiretroviral medication: susceptible, possible resistance, low resistance, moderate resistance, and high resistance. Any level of resistance, from low to high, is deemed resistant. The prevalence of drug resistance is calculated as the proportion of individuals with infections resistant to 3 drugs among all newly reported HIV-1 infections.</p></sec><sec id="s2-13"><title>Statement on Missing Data</title><p>Of the 213 enrolled participants, plasma amplification and sequencing were successful in 176 (82.6%). The 37 cases with missing sequence data did not differ significantly from those with available sequences in terms of age, marital status, education, or baseline CD4+ lymphocyte count (all <italic>P</italic>&#x003E;.05). For all 176 participants with sequence data, no values were missing for the primary outcomes (clustering and PDR), demographic variables, or covariates. The small proportion of missing sequences was handled by complete-case analysis for the molecular network and logistic regression and by using the total enrolled sample as the denominator for PDR prevalence to provide a conservative estimate.</p></sec><sec id="s2-14"><title>Ethical Considerations</title><p>The study was approved by the Biomedical Ethics Review Committee of Inner Mongolia Center for Disease Control and Prevention (approval number 202411282). All procedures were conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from every participant prior to blood sample collection. The consent form explicitly stated that the specimen and associated clinical data would be used for HIV molecular epidemiology research, including genetic sequencing and drug resistance analysis. All study data were deidentified. During sequencing and data analysis, participants were identified solely by unique study codes; personal identifiers were removed before data analysis. Only authorized research team members had access to the key data. No financial compensation was provided to participants, as sample and data collection were carried out as part of routine public health surveillance and clinical care, with no additional study-specific procedures beyond standard post-diagnosis evaluation. No images, photographs, or any other materials that could reveal the identity of individual participants are included in this manuscript or its supplementary files.</p></sec><sec id="s2-15"><title>Statistical Analysis</title><p>Demographic and baseline characteristics were summarized according to variable type. Categorical variables were expressed as frequencies and percentages, while continuous variables were assessed for normality and presented as medians with IQRs, as appropriate. To identify factors associated with clustering within the molecular transmission network, univariate logistic regression analysis was first performed to examine the association between each independent variable and the outcome variable (clustered vs nonclustered). To control for potential confounding effects, all factors found to be statistically significant (<italic>P</italic>&#x003C;.05) in the initial univariate analysis were included in a multivariate logistic regression model. A stepwise selection approach was used to construct the final model, retaining only those variables that remained statistically significant (<italic>P</italic>&#x003C;.05) after controlling for all other factors. Odds ratios (OR) and their corresponding 95% CIs were calculated to estimate the strength of associations. This modeling strategy was chosen because the outcome variable (molecular clustering) was binary, and logistic regression is the appropriate method for identifying independent predictors of binary outcomes in cross-sectional epidemiological data. Network assortativity was assessed using the assortativity coefficient (ra), which measures the tendency of nodes with similar attributes to connect with one another. The coefficient ranges from &#x2212;1 (disassortative) to 1 (assortative). All data analyses were performed using SPSS (version 25; IBM Corp) software, and figures were generated using GraphPad Prism (version 8; GraphPad Software LLC) and R (version 4.4.2; R Foundation for Statistical Computing) software.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Demographic Characteristics of the Study Population</title><p>This study involved gathering samples from 213 newly diagnosed HIV-1 cases among MSM, achieving a high sampling rate of 91.42% (n=213). Among newly reported cases, HIV-1 infections accounted for 32.86% (n=70) in 2022, 36.62% (n=78) in 2023, and 30.52% (n=65) in 2024. Of these, we successfully sequenced and analyzed 82.62% (n=176) of the samples. A total of 63 sequences were obtained in 2022, 64 in 2023, and 49 in 2024. As shown in <xref ref-type="table" rid="table1">Table 1</xref>, among the sequenced participants, the majority were 30&#x2010;50 years old (n=91, 51.70%). About 66.48% (n=117) were never-married individuals, and 79.55% (n=140) had at least a senior middle school education. CRF07_BC (n=100, 56.82%) was the most common subtype, followed by CRF01_AE (n=51, 28.98%), CRF55_01B (n=10, 5.68%), B (n=6, 3.41%), and other (n=9, 5.11%).</p></sec><sec id="s3-2"><title>Subtype Distribution Characteristics</title><p>The MSM population newly reported with HIV-1 infection over the past 3 years includes 7 subtypes and 4 URFs. The subtypes in this region are primarily composed of CRF07_BC (n=100, 56.82%) and CRF01_AE (n=51, 28.98%), followed by CRF55_01B (n=10, 5.68%), B (n=6, 3.41%), and others (n=9, 5.11%), including CRF67_01B (n=3, 33.33%), CRF59_01B (n=1, 11.11%), CRF08_BC (n=1, 11.11%), and URF (n=4, 44.44%; <xref ref-type="fig" rid="figure1">Figure 1</xref>). The CRF07_BC-N subclusters dominate in these current circulating strains (<xref ref-type="fig" rid="figure1">Figure 1B</xref>). Among never-married individuals under the age of 50 with a high school education or higher, CRF07_BC is a common subtype. In analyzing the demographic characteristics of HIV-1 infection among MSM, no significant association among infection report year, personal age, race, education level, marital status, or registration location and viral infection was found (<italic>P</italic>&#x003E;.05). There were significant differences in the genotypic composition of HIV-1 MSM infections across different CD4+ T lymphocyte counts (<italic>P</italic>&#x003C;.05).</p><fig position="float" id="figure1"><label>Figure 1.</label><caption><p>Phylogenetic tree of HIV-1 pol sequences inferred through maximum likelihood. (A) Shows the phylogenetic tree of all subtypes except unique recombination forms (URFs). (B) Shows the phylogenetic tree of CRF07_BC. Different colors represent different subclusters. CRF: circulating recombinant form.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="publichealth_v12i1e82208_fig01.png"/></fig></sec><sec id="s3-3"><title>Molecular Transmission Network Analysis</title><p>The number of clusters and the number of nodes included in the network were calculated separately for genetic distances ranging from 0.10% to 2%. The molecular transmission network was constructed using a genetic distance threshold of 1.30%, which yielded the largest number of clusters. Among the 176 pol gene sequences, 52 sequences (29.55%) were included as nodes in the network using a genetic distance threshold of 0.013, distributed across 19 clusters. Cluster sizes ranged from 2 to 6 nodes, 12 out of 19 clusters consisted of only 2 nodes connected by a homosexual transmission link, and 7 out of 19 clusters (36.84%) had 2 or more links. The largest cluster contained 6 nodes (11.54%) and 15 edges (32.61%). The median pairwise genetic distance was 0.0070 (IQR 0.0030&#x2010;0.0103). Node degrees ranged from 1 to 5, with most nodes in the network having a degree of 1. Among these 19 clusters, CRF07_BC accounted for 73.68% (n=14), CRF01_AE for 15.79% (n=3), and CRF55_01B for 10.53% (n=2). In addition, we identified 2 small drug resistance clusters in the network, both belonging to the CRF07_BC subtype. The key drug resistance mutations identified in the 2 clusters were Q58E and K103N, respectively.</p><p>Then, this study analyzed the assortative coefficients of demographic characteristics to better reflect assortative mixing within molecular transmission networks. The results indicate that the network exhibited significant assortative mixing by age (ra=0.41; <italic>P</italic>=.001), marital status (ra=0.408; <italic>P</italic>=.002), and educational attainment (ra=0.385; <italic>P</italic>=.001), rather than random mixing (<xref ref-type="fig" rid="figure2">Figures 2A-2F</xref>). Therefore, we analyzed the connection strength for these 3 demographic characteristics (<xref ref-type="fig" rid="figure3">Figures 3A-3C</xref>). The visualization results show that, regarding age, the connection strength was highest among older individuals (&#x003E;50 years; n=14, 31.11%). The connection strength was higher among married individuals (n=17, 37.78%). Nodes with a senior high school education and above were more likely to establish connections (n=26, 57.78%).</p><fig position="float" id="figure2"><label>Figure 2.</label><caption><p>Assortativity within the HIV-1 molecular transmission network. (A) Clusters of HIV-1 molecules coded by age group. (B) Assortativity analyzed by age group. (C) Clusters of HIV-1 molecules coded by marital status group. (D) Assortativity analyzed by marital status group. (E) Clusters of HIV-1 molecules coded by education level. (F) Assortativity analyzed by education level. The gray dashed line represents the 5% significance level. Pink vertical lines represent the actual assortativity. A value close to 1 indicates that the network exhibits high assortativity, meaning similar nodes are more likely to connect with each other.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="publichealth_v12i1e82208_fig02.png"/></fig><fig position="float" id="figure3"><label>Figure 3.</label><caption><p>The number of connections between nodes in a network under 3 different characteristics. (A) Age. (B) Marital status. (C) Education level. The numbers in the cross-grid units represent the number of correlations between HIV-1 individuals in the 2 groups.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="publichealth_v12i1e82208_fig03.png"/></fig></sec><sec id="s3-4"><title>Factors Associated With Clustering</title><p>Results from multivariate logistic regression indicated that, among MSM, marital status and subtype were most strongly associated with clusters of infections (<xref ref-type="table" rid="table2">Table 2</xref>). Compared with CRF01_AE, CRF07_BC was more likely to be associated with clusters of infections (OR 4.98; 95% CI 1.92&#x2010;12.94). Furthermore, compared with never-married individuals, those who were divorced or widowed were less likely to experience clustering (OR 0.27, 95% CI 0.08&#x2010;0.92). Other factors, such as age, year of reporting, educational level, ethnicity, pretreatment CD4+ T cell count, presence of PDR, and region of registration, were not associated with clustering (<xref ref-type="table" rid="table2">Table 2</xref>).</p><table-wrap id="t2" position="float"><label>Table 2.</label><caption><p>Analysis of risk factors for HIV-1 infection clusters among men who have sex with men (MSM).</p></caption><table id="table2" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Variables</td><td align="left" valign="bottom">Number, n(%)</td><td align="left" valign="bottom">Clustered, n (%)</td><td align="left" valign="bottom"><italic>P</italic> value</td><td align="left" valign="bottom">Crude OR<sup><xref ref-type="table-fn" rid="table2fn1">a</xref></sup><break/>(95% CI)</td><td align="left" valign="bottom"><italic>P</italic> value</td><td align="left" valign="bottom">Adjusted OR<break/>(95% CI)</td></tr></thead><tbody><tr><td align="left" valign="top" colspan="7">Reported year, n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>2022</td><td align="left" valign="top">63 (35.80)</td><td align="left" valign="top">21 (33.33)</td><td align="left" valign="top">&#x2014;<sup><xref ref-type="table-fn" rid="table2fn2">b</xref></sup></td><td align="left" valign="top">Reference</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>2023</td><td align="left" valign="top">64 (36.36)</td><td align="left" valign="top">18 (28.13)</td><td align="left" valign="top">.52</td><td align="left" valign="top">0.64 (0.67&#x2010;1.52)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>2024</td><td align="left" valign="top">49 (27.84)</td><td align="left" valign="top">13 (26.53)</td><td align="left" valign="top">.44</td><td align="left" valign="top">0.66 (0.26&#x2010;1.60)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="7">Subtype, n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>CRF<sup><xref ref-type="table-fn" rid="table2fn3">c</xref></sup>01_AE</td><td align="left" valign="top">51 (28.98)</td><td align="left" valign="top">6 (11.76)</td><td align="left" valign="top"/><td align="left" valign="top">Reference</td><td align="left" valign="top"/><td align="left" valign="top">Reference</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>CRF07_BC</td><td align="left" valign="top">100 (56.82)</td><td align="left" valign="top">41 (41.00)</td><td align="left" valign="top">&#x003C;.001</td><td align="left" valign="top">5.21 (2.04&#x2010;13.34)</td><td align="left" valign="top">&#x003C;.001</td><td align="left" valign="top">4.98 (1.92&#x2010;12.94)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>CRF55_01B</td><td align="left" valign="top">25 (14.20)</td><td align="left" valign="top">5 (20.00)</td><td align="left" valign="top">.06</td><td align="left" valign="top">2.78 (0.96&#x2010;8.01)</td><td align="left" valign="top">.06</td><td align="left" valign="top">2.86 (0.97&#x2010;8.44)</td></tr><tr><td align="left" valign="top" colspan="7">Age (years), n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>&#x003C;30</td><td align="left" valign="top">59 (33.52)</td><td align="left" valign="top">16 (27.12)</td><td align="left" valign="top"/><td align="left" valign="top">Reference</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>30&#x2010;50</td><td align="left" valign="top">91 (51.70)</td><td align="left" valign="top">26 (28.57)</td><td align="left" valign="top">.07</td><td align="left" valign="top">0.88 (0.42&#x2010;1.82)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>&#x003E;50</td><td align="left" valign="top">26 (14.77)</td><td align="left" valign="top">10 (38.46)</td><td align="left" valign="top">.48</td><td align="left" valign="top">0.70 (0.26&#x2010;1.90)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="7">Ethnicity, n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Han Chinese</td><td align="left" valign="top">162 (92.05)</td><td align="left" valign="top">48 (29.63)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">Reference</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Mongol</td><td align="left" valign="top">12 (6.82)</td><td align="left" valign="top">3 (25.00)</td><td align="left" valign="top">.73</td><td align="left" valign="top">1.26 (0.32-4.87)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Hui</td><td align="left" valign="top">2 (1.14)</td><td align="left" valign="top">1 (50.00)</td><td align="left" valign="top">.54</td><td align="left" valign="top">0.42 (0.02-6.87)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="7">Registered residence, n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Baotou</td><td align="left" valign="top">155 (88.07)</td><td align="left" valign="top">47 (30.32)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">Reference</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Other regions</td><td align="left" valign="top">16 (9.09)</td><td align="left" valign="top">4 (25.00)</td><td align="left" valign="top">.66</td><td align="left" valign="top">1.30 (0.40-4.26)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Other provinces</td><td align="left" valign="top">5 (2.84)</td><td align="left" valign="top">1 (20.00)</td><td align="left" valign="top">.62</td><td align="left" valign="top">1.74 (0.18-15.99)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="7">Marital status, n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Never married</td><td align="left" valign="top">117 (66.48)</td><td align="left" valign="top">29 (24.79)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">Reference</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">Reference</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Married</td><td align="left" valign="top">34 (19.32)</td><td align="left" valign="top">17 (50.00)</td><td align="left" valign="top">.01</td><td align="left" valign="top">0.34 (0.16-0.76)</td><td align="left" valign="top">.61</td><td align="left" valign="top">0.75 (0.24-2.26)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Divorced/widowed</td><td align="left" valign="top">25 (14.20)</td><td align="left" valign="top">6 (24.00)</td><td align="left" valign="top">.55</td><td align="left" valign="top">1.38 (0.48-4.00)</td><td align="left" valign="top">.04</td><td align="left" valign="top">0.269 (0.08-0.92)</td></tr><tr><td align="left" valign="top" colspan="7">Education level, n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Primary school and illiteracy</td><td align="left" valign="top">10 (5.68)</td><td align="left" valign="top">3 (33.33)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">Reference</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Junior middle school</td><td align="left" valign="top">26 (14.77)</td><td align="left" valign="top">9 (34.62)</td><td align="left" valign="top">.96</td><td align="left" valign="top">0.96 (0.20-4.72)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Senior middle school and above</td><td align="left" valign="top">140 (79.55)</td><td align="left" valign="top">40 (28.57)</td><td align="left" valign="top">.96</td><td align="left" valign="top">1.04 (0.26-4.20)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="7">Occupation, n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Unemployment</td><td align="left" valign="top">74 (42.05)</td><td align="left" valign="top">19 (25.68)</td><td align="left" valign="top"/><td align="left" valign="top">Reference</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Farmers and herders</td><td align="left" valign="top">17 (9.66)</td><td align="left" valign="top">9 (52.94)</td><td align="left" valign="top">.03</td><td align="left" valign="top">0.31 (0.10-0.91)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Students</td><td align="left" valign="top">13 (7.39)</td><td align="left" valign="top">2 (15.38)</td><td align="left" valign="top">.34</td><td align="left" valign="top">1.90 (0.38-9.36)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Business service</td><td align="left" valign="top">19 (10.80)</td><td align="left" valign="top">6 (31.58)</td><td align="left" valign="top">.60</td><td align="left" valign="top">0.74 (0.24-2.24)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>others</td><td align="left" valign="top">53 (30.11)</td><td align="left" valign="top">16 (30.19)</td><td align="left" valign="top">.58</td><td align="left" valign="top">0.80 (0.36-1.75)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="7">CD4+<sup><xref ref-type="table-fn" rid="table2fn4">d</xref></sup> T cell count, n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>&#x003C;200</td><td align="left" valign="top">43 (24.43)</td><td align="left" valign="top">13 (30.23)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">Reference</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>200&#x2010;500</td><td align="left" valign="top">91 (51.70)</td><td align="left" valign="top">29 (31.87)</td><td align="left" valign="top">.56</td><td align="left" valign="top">0.78 (0.36-1.74)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>&#x003E;500</td><td align="left" valign="top">42 (23.86)</td><td align="left" valign="top">10 (23.81)</td><td align="left" valign="top">.67</td><td align="left" valign="top">1.24 (0.468-3.28)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="7">Drug resistance, n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Yes</td><td align="left" valign="top">14 (7.95)</td><td align="left" valign="top">6 (42.86)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">Reference</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>No</td><td align="left" valign="top">162 (92.05)</td><td align="left" valign="top">46 (28.40)</td><td align="left" valign="top">.26</td><td align="left" valign="top">1.89 (0.62-5.75)</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><p><sup>a</sup>OR: odds ratio.</p></fn><fn id="table2fn2"><p><sup>b</sup>Not available.</p></fn><fn id="table2fn3"><p><sup>c</sup>CRF: circulating recombinant form.</p></fn><fn id="table2fn4"><p><sup>d</sup>CD4+: cluster of differentiation 4.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-5"><title>Drug Resistance in HIV&#x2010;1&#x2010;Infected MSM</title><p>The prevalence of PDR increased from 4.29% (n=3) in 2022 to 9.23% (n=6) in 2024. The overall prevalence of PDR in the HIV-1-infected MSM population was 6.57% (n=14). A chi-square test for trend revealed a significant increasing trend in PDR prevalence over the 3-year period (<italic>&#x03C7;</italic><sup>2</sup><sub>1</sub>=17.885; <italic>P</italic>&#x003C;.001), showing an increasing trend in PDR. NNRTI resistance was the most common (n=8, 3.76%), followed by PI resistance (n=5, 2.35%), and NRTI resistance (n=3, 1.14%).</p><p>For HIV-1-infected MSM in Baotou, NNRTIs were associated with the most common resistance mutations, with the K103N mutation (n=5, 2.35%) being the most frequent, followed by L100I (n=2, 0.94%). For NRTIs resistance, the most frequently detected mutation was D67N/del (n=2, 0.94%), while for PIs resistance, Q58E (n=3, 1.41%) was the most common mutation.</p><p>As shown in <xref ref-type="table" rid="table3">Table 3</xref>, mutations associated with NNRTIs primarily result in moderate/high resistance to doravirine (DOR), efavirenz (EFV), etravirine (ETR), nevirapine (NVP), and rilpivirine (RPV), with 5 cases exhibiting high resistance to EFV and 7 cases exhibiting high resistance to NVP. Mutations associated with PIs primarily result in low resistance to nelfinavir (NFV) and tipranavir boosted with ritonavir (TPV/r). Mutations associated with NRTIs primarily result in moderate resistance to abacavir (ABC), zidovudine (AZT), lamivudine (3TC), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF), and high resistance to stavudine (D4T) and didanosine (DDI). In addition, this study used chi-square tests to assess the association between subtypes and the presence of resistance. Significant differences were observed, with resistance more likely to be found in the CRF07_BC subtype (<italic>&#x03C7;</italic><sup>2</sup><sub>8</sub>=90.44; <italic>P&#x003C;</italic>.001).</p><table-wrap id="t3" position="float"><label>Table 3.</label><caption><p>Distribution of drug susceptibility and resistance mutations in HIV-1-infected men who have sex with men (MSM).</p></caption><table id="table3" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" colspan="2">Drugs</td><td align="left" valign="bottom" colspan="2">Low-Level resistance</td><td align="left" valign="bottom" colspan="2">Intermediate resistance</td><td align="left" valign="bottom" colspan="2">High-Level resistance</td></tr></thead><tbody><tr><td align="left" valign="top" colspan="2"/><td align="left" valign="top">Numbers</td><td align="left" valign="top">Mutations</td><td align="left" valign="top">Numbers</td><td align="left" valign="top">Mutations</td><td align="left" valign="top">Numbers</td><td align="left" valign="top">Mutations</td></tr><tr><td align="left" valign="top" colspan="2">PIs<sup><xref ref-type="table-fn" rid="table3fn1">a</xref></sup></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>NFV<sup><xref ref-type="table-fn" rid="table3fn2">b</xref></sup></td><td align="left" valign="top">1</td><td align="left" valign="top">N83D</td><td align="left" valign="top">1</td><td align="left" valign="top">M46I</td><td align="left" valign="top">&#x2014;<sup><xref ref-type="table-fn" rid="table3fn3">c</xref></sup></td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>TPV/r<sup><xref ref-type="table-fn" rid="table3fn4">d</xref></sup></td><td align="left" valign="top">4</td><td align="left" valign="top">Q58E</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="2">NRTIs<sup><xref ref-type="table-fn" rid="table3fn5">e</xref></sup></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>ABC<sup><xref ref-type="table-fn" rid="table3fn6">f</xref></sup></td><td align="left" valign="top">2</td><td align="left" valign="top">T215Y</td><td align="left" valign="top">1</td><td align="left" valign="top">D67del+S86del</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>AZT<sup><xref ref-type="table-fn" rid="table3fn7">g</xref></sup></td><td align="left" valign="top">1</td><td align="left" valign="top">D67N+K70N</td><td align="left" valign="top">1</td><td align="left" valign="top">T215Y</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>D4T<sup><xref ref-type="table-fn" rid="table3fn8">h</xref></sup></td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">1</td><td align="left" valign="top">D67n+K70N</td><td align="left" valign="top">1</td><td align="left" valign="top">D67del+S86del</td></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>DDI<sup><xref ref-type="table-fn" rid="table3fn9">i</xref></sup></td><td align="left" valign="top">1</td><td align="left" valign="top">D67N+K70N</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">1</td><td align="left" valign="top">D67del+S86del</td></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>3TC<sup><xref ref-type="table-fn" rid="table3fn10">j</xref></sup></td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">1</td><td align="left" valign="top">D67del+S86del</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>FTC<sup><xref ref-type="table-fn" rid="table3fn11">k</xref></sup></td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">1</td><td align="left" valign="top">D67del+S86del</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>TDF<sup><xref ref-type="table-fn" rid="table3fn12">l</xref></sup></td><td align="left" valign="top">1</td><td align="left" valign="top">D67N+K70N</td><td align="left" valign="top">1</td><td align="left" valign="top">D67del+S86del</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="2">NNRTIs<sup><xref ref-type="table-fn" rid="table3fn13">m</xref></sup></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>DOR<sup><xref ref-type="table-fn" rid="table3fn14">n</xref></sup></td><td align="left" valign="top">2</td><td align="left" valign="top">L100I</td><td align="left" valign="top">1</td><td align="left" valign="top">K103N,P225H</td><td align="left" valign="top">1</td><td align="left" valign="top">F227L</td></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>EFV<sup><xref ref-type="table-fn" rid="table3fn15">o</xref></sup></td><td align="left" valign="top">1</td><td align="left" valign="top">F227L</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">7</td><td align="left" valign="top">K103N,P225H,L100I</td></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>ETR<sup><xref ref-type="table-fn" rid="table3fn16">p</xref></sup></td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">2</td><td align="left" valign="top">L100I</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>NVP<sup><xref ref-type="table-fn" rid="table3fn17">q</xref></sup></td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">1</td><td align="left" valign="top">F227L</td><td align="left" valign="top">7</td><td align="left" valign="top">K103N,P225H,L100I</td></tr><tr><td align="left" valign="top" colspan="2"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>RPV<sup><xref ref-type="table-fn" rid="table3fn18">r</xref></sup></td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">&#x2014;</td><td align="left" valign="top">2</td><td align="left" valign="top">L100I</td></tr></tbody></table><table-wrap-foot><fn id="table3fn1"><p><sup>a</sup>PI: protease inhibitor.</p></fn><fn id="table3fn2"><p><sup>b</sup>NFV: nelfinavir.</p></fn><fn id="table3fn3"><p><sup>c</sup>Not applicable.</p></fn><fn id="table3fn4"><p><sup>d</sup>TPV/r: tipranavir boosted with ritonavir.</p></fn><fn id="table3fn5"><p><sup>e</sup>NRTI: nucleoside reverse transcriptase inhibitor.</p></fn><fn id="table3fn6"><p><sup>f</sup>ABC: abacavir.</p></fn><fn id="table3fn7"><p><sup>g</sup>AZT: zidovudine.</p></fn><fn id="table3fn8"><p><sup>h</sup>D4T: stavudine.</p></fn><fn id="table3fn9"><p><sup>i</sup>DDI: didanosine.</p></fn><fn id="table3fn10"><p><sup>j</sup>3TC: lamivudine.</p></fn><fn id="table3fn11"><p><sup>k</sup>FTC: emtricitabine.</p></fn><fn id="table3fn12"><p><sup>l</sup>TDF: tenofovir disoproxil fumarate.</p></fn><fn id="table3fn13"><p><sup>m</sup>NNRTI: nonnucleoside reverse transcriptase inhibitor.</p></fn><fn id="table3fn14"><p><sup>n</sup>DOR: doravirine.</p></fn><fn id="table3fn15"><p><sup>o</sup>EFV: efavirenz.</p></fn><fn id="table3fn16"><p><sup>p</sup>ETR: etravirine.</p></fn><fn id="table3fn17"><p><sup>q</sup>NVP: nevirapine.</p></fn><fn id="table3fn18"><p><sup>r</sup>RPV: rilpivirine.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><sec id="s4-1"><title>Principal Findings</title><p>China&#x2019;s economic development is characterized by substantial regional disparities. Western regions are geographically vast, relatively underdeveloped economically, and feature widely dispersed populations, which pose considerable challenges for disease prevention and control. Targeted interventions based on HIV-1 molecular transmission networks have been widely implemented in economically developed regions and have demonstrated promising effectiveness in HIV prevention and control. Meanwhile, with the continuous advancement of NGS technologies, these approaches have also been increasingly applied to HIV drug resistance surveillance, thereby providing improved guidance for ART.</p><p>The Inner Mongolia Autonomous Region, located in northern China&#x2019;s border area, remains relatively underdeveloped economically and has limited experience in the application of novel HIV prevention technologies and methodologies. Therefore, this study selected Baotou, Inner Mongolia, as the study site and applied HIV-1 molecular transmission network analysis combined with NGS technology to investigate transmission clustering and pretreatment drug resistance among local HIV-infected individuals. With a sampling rate exceeding 90%, the study is representative of this population. The findings are expected to provide more precise and efficient strategies for HIV prevention and control in Baotou and potentially across the entire Inner Mongolia Autonomous Region.</p><p>Demographic analysis indicates that HIV-1-infected MSM in Baotou tend to be younger, never-married, and better educated. Similar results have been reported in other studies on MSM populations [<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref>]. Previous studies have shown that young MSM in the Inner Mongolia Autonomous Region have a high level of HIV/AIDS knowledge. However, the proportion of commercial sex has increased annually, and the rate of consistent condom use remains low, resulting in a disconnect between knowledge and behavior. This may explain the relatively high infection rate among young MSM in the region [<xref ref-type="bibr" rid="ref33">33</xref>]. For MSM engaging in unprotected receptive anal sex, interventions that reduce infection risk are critical. Therefore, this group should be a priority for prevention and control efforts, with screening expanded to include both infected individuals and their sexual partners.</p><p>Among HIV-1-infected MSM in Baotou, the predominant subtypes are CRF07_BC and CRF01_AE. Phylogenetic analysis indicates that the CRF07_BC-N subclusters are the dominant epidemiological cluster. CRF07_BC-N subclusters originated in Yunnan Province and are primarily transmitted among MSM [<xref ref-type="bibr" rid="ref34">34</xref>]. Compared with the CRF07_BC-O subclusters, CRF07_BC-N subclusters exhibit higher network density, interprovincial transmission rates, and interregional transmission rates [<xref ref-type="bibr" rid="ref35">35</xref>]. The results of this study further indicate that this lineage may have undergone large-scale interprovincial and intraprovincial transmission across China. Therefore, strengthening the diagnosis and surveillance of HIV-1-infected MSM is crucial for controlling the spread of CRF07_BC. With the increase in homosexual transmission, CRF01_AE has become one of the predominant strains among MSM [<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref>]. In Hebei Province [<xref ref-type="bibr" rid="ref38">38</xref>] and Heilongjiang Province [<xref ref-type="bibr" rid="ref39">39</xref>], which border the Inner Mongolia Autonomous Region, the proportion of CRF01_AE among MSM is the highest, indicating that the predominant circulating subtypes among MSM exhibit regional characteristics. Recent studies have identified novel recombinant strains (CRF01_AE/CRF07_BC) among MSM in Beijing [<xref ref-type="bibr" rid="ref40">40</xref>]. The high frequency of recombination between these 2 subtypes underscores the importance of closely monitoring viral transmission and evolution in high-risk areas and populations. Therefore, continuous surveillance of HIV-1 subtype diversity and transmission dynamics is essential for effective epidemic control.</p><p>Molecular network analysis has revealed the transmission patterns of HIV-1 among MSM. Compared to individuals infected with the CRF01_AE strain, those infected with the CRF07_BC strain showed a stronger association with clustered HIV-1 transmission within the network. These findings are consistent with those observed in Chongqing [<xref ref-type="bibr" rid="ref41">41</xref>] and Guangxi [<xref ref-type="bibr" rid="ref42">42</xref>]. Pathogenic studies of the CRF07_BC strain indicate a relatively low baseline viral load. A 7-amino acid deletion (&#x0394;7) in the p6gag region impairs viral maturation and release, leading to reduced replicative capacity [<xref ref-type="bibr" rid="ref43">43</xref>]. Because of its transmission advantages, CRF07_BC may continue to play an important role in HIV transmission among MSM populations in China [<xref ref-type="bibr" rid="ref44">44</xref>]. Compared with MSM who have never been married, divorced, or widowed, MSM are associated with a lower risk of forming transmission clusters. MSM who have never been married are typically younger and may engage in high-risk sexual behavior, such as frequently changing sexual partners and having unprotected sex. A greater number of sexual partners may increase opportunities for HIV transmission, which in turn may facilitate viral clustering and spread [<xref ref-type="bibr" rid="ref44">44</xref>]. Although this group has a relatively high level of education, previous studies have shown that there is a discrepancy between their knowledge of HIV/AIDS and their actual behavior in the Inner Mongolia Autonomous Region [<xref ref-type="bibr" rid="ref33">33</xref>]. Our findings merely indicate that, among HIV-1-infected individuals in Baotou, divorced or widowed MSM are less strongly associated with viral clustering and transmission compared to MSM who have never been married. To confirm these results, further validation through expanded sampling and epidemiological investigations is required.</p><p>In this study, the assortative coefficients for age group, marital status, and educational level were statistically significant. HIV-1-infected individuals within the same age group, marital status, and educational level tended to cluster within the network. The connection patterns indicated that older individuals, married individuals, and those with higher educational levels were more likely to connect with similar nodes within the network. Analyzing the assortative characteristics of nodes within a network can rapidly identify key nodes [<xref ref-type="bibr" rid="ref45">45</xref>]. Therefore, during epidemic surveillance, it is necessary to integrate network indicators with molecular transmission networks to provide critical information on priority populations for population-based epidemic prevention and control, formulate interventions targeting HIV transmission hotspots, and use public health resources more efficiently to achieve precise HIV prevention and control [<xref ref-type="bibr" rid="ref46">46</xref>].</p><p>This study assessed the prevalence of PDR and the presence of drug resistance mutations (DRMs) among MSM in Baotou over the past 3 years. The local PDR rate in Baotou was 6.57%, slightly lower than the national average (7.4% in 2022) [<xref ref-type="bibr" rid="ref47">47</xref>]. This difference may be attributed to the more stable demographic structure of the MSM population in Baotou, which reduces the likelihood of cross-regional transmission of drug-resistant strains. Despite being slightly below the national average, the local PDR rate still exceeds the World Health Organization (WHO) warning threshold of 5%. This study observed the highest frequency of DRMs among NNRTIs, followed by NRTIs, with resistance of the CRF07_BC subtype being the predominant type. This is consistent with findings reported in certain cities [<xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref21">21</xref>]. This finding may be associated with the relatively low genetic barrier of NNRTIs and the widespread use of first-line treatment regimens [<xref ref-type="bibr" rid="ref48">48</xref>-<xref ref-type="bibr" rid="ref50">50</xref>]. High levels of resistance were primarily observed for drugs such as EFV, NVP, and D4T, highlighting the potential impact of long-term use of the same antiviral treatment regimen and urging the exploration of effective alternative regimens [<xref ref-type="bibr" rid="ref51">51</xref>,<xref ref-type="bibr" rid="ref52">52</xref>]. The PDR rate for NNRTIs was 3.76%, higher than that for NRTIs and PIs. Studies indicate that the increase in PDR prevalence is primarily driven by NNRTI resistance [<xref ref-type="bibr" rid="ref53">53</xref>]. Additionally, it is worth noting that the proportion of dual resistance to NRTIs and NNRTIs among individuals with drug resistance is 14.29%, which limits the options for second-line treatment regimens. This suggests that resistance testing should be conducted on patients with virological failure before considering second-line treatment regimens.</p><p>Then this study analyzed the distribution of DRMs. First, the most commonly detected NNRTI-associated resistance mutation is K103N. Multiple studies have demonstrated that K103 is the most common DRM site for NNRTIs used as first-line antiviral drugs, and this mutation is closely associated with resistance to EFV and NVP, and it is also commonly found in CRF07_BC [<xref ref-type="bibr" rid="ref54">54</xref>-<xref ref-type="bibr" rid="ref57">57</xref>]. Our research results also prove this point. Therefore, particular vigilance is required for the K103N mutation. The next most common DRM is L100I, which can lead to moderate to high resistance to NVP, RPV, and DPV. We found that several drug-resistant individuals exhibited varying levels of resistance to DOR. A Dutch study demonstrated that DOR holds promise for more effective and cost-effective treatment for patients living with HIV [<xref ref-type="bibr" rid="ref58">58</xref>], but the results indicate that close monitoring will still be necessary when using DOR in the future.</p><p>Our research team recently published a comprehensive analysis of sexually acquired HIV-1 cases in Baotou, which identified older heterosexual men as key drivers of local transmission networks [<xref ref-type="bibr" rid="ref23">23</xref>]. The present study is a logical extension of that work, specifically designed to conduct an in-depth, dedicated molecular investigation of the MSM population&#x2014;the group accounting for the highest proportion of newly reported HIV-1 cases in Inner Mongolia. While the two studies share the same geographical setting and methodological framework, they address fundamentally distinct research questions and target populations, and are therefore complementary rather than redundant. This study demonstrates that MSM remain the core population sustaining the epidemic and require dedicated, population-specific attention. Together, these two studies provide a more complete picture of the HIV-1 epidemic in Baotou, with the current manuscript filling a critical gap by delivering the granular, population-specific data necessary for designing targeted interventions for MSM in Inner Mongolia.</p></sec><sec id="s4-2"><title>Limitations</title><p>This study has certain limitations. First, a portion of the samples was collected during the COVID-19 pandemic, and changes in epidemic prevention measures and health care&#x2013;seeking behaviors may have resulted in incomplete sampling. Some transmission chains may not have been effectively identified because infected individuals failed to seek medical care, undergo testing, or be included in the surveillance system in a timely manner. This resulted in an incomplete description of the local HIV transmission network and may have underestimated the size of certain transmission clusters. Future studies could incorporate samples and data from multiple time periods to validate these results and reduce the impact of sampling bias on the identification of transmission chains. Second, the proportion of potentially nondisclosed MSM (pnMSM) in the sample may have been underestimated, and reporting bias may have existed during epidemiological data collection, which could introduce bias in cluster analysis and pre-treatment resistance rates. Future studies should include pnMSM to reduce potential reporting bias. Finally, testing for integrase strand transfer inhibitors (INSTI)&#x2013;associated resistance has not yet been included. Although the reported rate of INSTI-associated resistance is currently low, the potential risk of resistance cannot be ignored given the expanding use of these drugs. Future studies will focus on conducting resistance analyses for these drugs.</p></sec><sec id="s4-3"><title>Conclusion</title><p>Unlike previous studies that primarily focused on high-burden southeastern and coastal regions of China, this study addresses an important geographical gap by investigating HIV-1 molecular transmission clusters and pretreatment drug resistance among MSM in Baotou, a major city in northern China.</p><p>This study is distinguished by its use of NGS technology to provide a comprehensive characterization of the local HIV epidemic by integrating molecular transmission network analysis, assortative mixing analysis, and pretreatment drug resistance surveillance. These findings demonstrate that the high clustering of CRF07_BC and the predominance of NNRTI resistance are not confined to coastal regions with severe HIV epidemics but are also present in northern border regions characterized by different demographic and behavioral patterns.</p><p>These results highlight the importance of incorporating molecular network surveillance into routine HIV monitoring systems to identify high-risk transmission clusters and support precision public health interventions. In particular, younger, unmarried, and highly educated MSM exhibited a greater likelihood of being HIV-1-infected and should therefore be prioritized for targeted prevention strategies. Furthermore, surveillance of pretreatment drug resistance may facilitate the optimization of region-specific first-line antiretroviral regimens and improve the efficient allocation of limited health care resources.</p><p>In the Inner Mongolia Autonomous Region, the geographically dispersed population and relatively limited health care resources have hindered the widespread implementation of advanced HIV surveillance technologies and targeted intervention strategies. These findings may provide important evidence for molecular surveillance-based HIV prevention strategies in other resource-limited border regions of China.</p></sec></sec></body><back><ack><p>The authors would like to express their sincere gratitude to the study participants for their invaluable support. The authors also thank the dedicated staff at the clinical sites and the Inner Mongolia Autonomous Region Center for Disease Control and Prevention for their assistance in gathering blood samples and data.</p><p/></ack><notes><sec><title>Generative AI Use</title><p>The authors declare the use of generative AI (GenAI) in the research and writing process. According to the GAIDeT (Generative AI Delegation) taxonomy (2025), the following tasks were delegated to GenAI tools under full human supervision:</p><p>- Translation</p><p>The GenAI tool used was: Grammarly.</p><p>Responsibility for the final manuscript lies entirely with the authors.</p><p>GenAI tools are not listed as authors and do not bear responsibility for the final outcomes.</p></sec><sec><title>Funding</title><p>This work was supported by the National Key Research and Development Program of China under Grant numbers (grant 2022YFC2304903), the National Natural Science Foundation of China under Grant number (grant 82173583), and the Natural Science Foundation of the Inner Mongolia Autonomous Region of China (grant 2025MS08104). The funders had no role in the study design, data collection, analysis, data interpretation, manuscript writing, or the decision to submit the paper for publication.</p></sec><sec><title>Data Availability</title><p>The data presented in this study are not publicly available due to privacy and ethical restrictions related to the sensitive nature of the information.</p></sec></notes><fn-group><fn fn-type="con"><p>Conceptualization: LL, HY, HL</p><p>Data curation: YL, ZL, BB</p><p>Formal analysis: HL</p><p>Methodology: HL, YL, LJ, WH</p><p>Software: YL, BZ, XW, JH</p><p>Visualization: YL</p><p>Supervision: LL, HY</p><p>Validation: YZ, XL</p><p>Project administration: LL, HL</p><p>Writing &#x2013; original draft: YL</p><p>Writing &#x2013; review &#x0026; editing: HL, YL, JW</p></fn><fn fn-type="conflict"><p>None declared.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">3TC</term><def><p>lamivudine</p></def></def-item><def-item><term id="abb2">ABC</term><def><p>abacavir</p></def></def-item><def-item><term id="abb3">AOR</term><def><p>adjusted odds ratio</p></def></def-item><def-item><term id="abb4">ART</term><def><p>antiretroviral therapy</p></def></def-item><def-item><term id="abb5">AZT</term><def><p>zidovudine</p></def></def-item><def-item><term id="abb6">CD4+</term><def><p>cluster of differentiation 4</p></def></def-item><def-item><term id="abb7">CDC</term><def><p>US Centers for Disease Control and Prevention</p></def></def-item><def-item><term id="abb8">CRFs</term><def><p>Circulating Recombinant Forms</p></def></def-item><def-item><term id="abb9">D4T</term><def><p>stavudine</p></def></def-item><def-item><term id="abb10">DDI</term><def><p>didanosine</p></def></def-item><def-item><term id="abb11">DOR</term><def><p>doravirine</p></def></def-item><def-item><term id="abb12">DRM</term><def><p>drug resistance mutation</p></def></def-item><def-item><term id="abb13">EFV</term><def><p>efavirenz</p></def></def-item><def-item><term id="abb14">ETR</term><def><p>etravirine</p></def></def-item><def-item><term id="abb15">FTC</term><def><p>emtricitabine</p></def></def-item><def-item><term id="abb16">INSTI</term><def><p>integrase strand transfer inhibitor</p></def></def-item><def-item><term id="abb17">MSM</term><def><p>men who sex with men</p></def></def-item><def-item><term id="abb18">NCAIDS</term><def><p>National Center for AIDS/Sexually Transmitted Disease Control and Prevention</p></def></def-item><def-item><term id="abb19">NFV</term><def><p>nelfinavir</p></def></def-item><def-item><term id="abb20">NGS</term><def><p>next-generation sequencing</p></def></def-item><def-item><term id="abb21">NNRTI</term><def><p>nonnucleoside reverse transcriptase inhibitor</p></def></def-item><def-item><term id="abb22">NRTIs</term><def><p>nucleoside reverse transcriptase inhibitors</p></def></def-item><def-item><term id="abb23">NVP</term><def><p>nevirapine</p></def></def-item><def-item><term id="abb24">OR</term><def><p>odds ratio</p></def></def-item><def-item><term id="abb25">PCR</term><def><p>polymerase chain reaction</p></def></def-item><def-item><term id="abb26">PDR</term><def><p>pretreatment HIV drug resistance</p></def></def-item><def-item><term id="abb27">PI</term><def><p>protease inhibitor</p></def></def-item><def-item><term id="abb28">pnMSM</term><def><p>potential nondisclosed men who have sex with men</p></def></def-item><def-item><term id="abb29">PR</term><def><p>protease</p></def></def-item><def-item><term id="abb30">RPV</term><def><p>rilpivirine</p></def></def-item><def-item><term id="abb31">RT</term><def><p>reverse transcriptase</p></def></def-item><def-item><term id="abb32">TDF</term><def><p>tenofovir disoproxil fumarate</p></def></def-item><def-item><term id="abb33">TPV/r</term><def><p>tipranavir boosted with ritonavir</p></def></def-item><def-item><term id="abb34">URF</term><def><p>unique recombination form</p></def></def-item><def-item><term id="abb35">WHO</term><def><p>World Health Organization</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><label>1</label><nlm-citation citation-type="web"><article-title>HIV diagnoses, deaths, and prevalence: 2025</article-title><source>Centers for Disease Control and Prevention</source><year>2025</year><access-date>2025-07-21</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html">https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html</ext-link></comment></nlm-citation></ref><ref id="ref2"><label>2</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>L</given-names> </name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names> </name><name name-style="western"><surname>Jin</surname><given-names>Q</given-names> </name></person-group><article-title>Meta-analysis: prevalence of HIV infection and syphilis among MSM in China</article-title><source>Sex Transm Infect</source><year>2009</year><month>09</month><volume>85</volume><issue>5</issue><fpage>354</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1136/sti.2008.034702</pub-id><pub-id pub-id-type="medline">19351623</pub-id></nlm-citation></ref><ref id="ref3"><label>3</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>X</given-names> </name><name name-style="western"><surname>Zhong</surname><given-names>X</given-names> </name><name name-style="western"><surname>Peng</surname><given-names>B</given-names> </name><etal/></person-group><article-title>Prevalence and associated risk characteristics of HIV infection based on anal sexual role among men who have sex with men: a multi-city cross-sectional study in Western China</article-title><source>Int J Infect Dis</source><year>2016</year><month>08</month><volume>49</volume><fpage>111</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2016.06.009</pub-id><pub-id pub-id-type="medline">27312581</pub-id></nlm-citation></ref><ref id="ref4"><label>4</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>MJ</given-names> </name><name name-style="western"><surname>Peng</surname><given-names>B</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>ZF</given-names> </name><etal/></person-group><article-title>The prevalence of HIV among MSM in China: a large-scale systematic analysis</article-title><source>BMC Infect Dis</source><year>2019</year><month>11</month><day>27</day><volume>19</volume><issue>1</issue><fpage>1000</fpage><pub-id pub-id-type="doi">10.1186/s12879-019-4559-1</pub-id><pub-id pub-id-type="medline">31775654</pub-id></nlm-citation></ref><ref id="ref5"><label>5</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>NK</given-names> </name><name name-style="western"><surname>Goldstein</surname><given-names>ND</given-names> </name><name name-style="western"><surname>Welles</surname><given-names>SL</given-names> </name></person-group><article-title>Bias adjustment techniques are underutilized in HIV sexual risk estimation: a systematic review</article-title><source>Int J Environ Res Public Health</source><year>2018</year><month>08</month><day>9</day><volume>15</volume><issue>8</issue><fpage>1696</fpage><pub-id pub-id-type="doi">10.3390/ijerph15081696</pub-id><pub-id pub-id-type="medline">30096874</pub-id></nlm-citation></ref><ref id="ref6"><label>6</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>E</given-names> </name><name name-style="western"><surname>Skaathun</surname><given-names>B</given-names> </name><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names> </name></person-group><article-title>Sexual, social, and genetic network overlap: a socio-molecular approach toward public health intervention of HIV</article-title><source>Am J Public Health</source><year>2018</year><month>11</month><volume>108</volume><issue>11</issue><fpage>1528</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.2105/AJPH.2018.304438</pub-id><pub-id pub-id-type="medline">30252515</pub-id></nlm-citation></ref><ref id="ref7"><label>7</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oster</surname><given-names>AM</given-names> </name><name name-style="western"><surname>Wertheim</surname><given-names>JO</given-names> </name><name name-style="western"><surname>Hernandez</surname><given-names>AL</given-names> </name><name name-style="western"><surname>Ocfemia</surname><given-names>MCB</given-names> </name><name name-style="western"><surname>Saduvala</surname><given-names>N</given-names> </name><name name-style="western"><surname>Hall</surname><given-names>HI</given-names> </name></person-group><article-title>Using molecular HIV surveillance data to understand transmission between subpopulations in the United States</article-title><source>J Acquir Immune Defic Syndr</source><year>2015</year><month>12</month><day>1</day><volume>70</volume><issue>4</issue><fpage>444</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000000809</pub-id><pub-id pub-id-type="medline">26302431</pub-id></nlm-citation></ref><ref id="ref8"><label>8</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandhi</surname><given-names>RT</given-names> </name><name name-style="western"><surname>Bedimo</surname><given-names>R</given-names> </name><name name-style="western"><surname>Hoy</surname><given-names>JF</given-names> </name><etal/></person-group><article-title>Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society-USA panel</article-title><source>JAMA</source><year>2023</year><month>01</month><day>3</day><volume>329</volume><issue>1</issue><fpage>63</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.22246</pub-id><pub-id pub-id-type="medline">36454551</pub-id></nlm-citation></ref><ref id="ref9"><label>9</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smiley</surname><given-names>CL</given-names> </name><name name-style="western"><surname>Rebeiro</surname><given-names>PF</given-names> </name><name name-style="western"><surname>Cesar</surname><given-names>C</given-names> </name><etal/></person-group><article-title>Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study</article-title><source>Lancet HIV</source><year>2021</year><month>05</month><volume>8</volume><issue>5</issue><fpage>e266</fpage><lpage>e273</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(20)30358-1</pub-id><pub-id pub-id-type="medline">33891877</pub-id></nlm-citation></ref><ref id="ref10"><label>10</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>J</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>J</given-names> </name><name name-style="western"><surname>Qin</surname><given-names>F</given-names> </name><etal/></person-group><article-title>Effect of antiretroviral therapy on the mortality of HIV-1 infection long-term non-progressors: a cohort study</article-title><source>BMC Infect Dis</source><year>2025</year><month>01</month><day>16</day><volume>25</volume><issue>1</issue><fpage>72</fpage><pub-id pub-id-type="doi">10.1186/s12879-025-10448-x</pub-id><pub-id pub-id-type="medline">39819447</pub-id></nlm-citation></ref><ref id="ref11"><label>11</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Zyl</surname><given-names>GU</given-names> </name><name name-style="western"><surname>Grobbelaar</surname><given-names>CJ</given-names> </name><name name-style="western"><surname>Claassen</surname><given-names>M</given-names> </name><name name-style="western"><surname>Bock</surname><given-names>P</given-names> </name><name name-style="western"><surname>Preiser</surname><given-names>W</given-names> </name></person-group><article-title>Moderate levels of pre-therapy drug resistance (PDR) in a generalised epidemic: time for better first-line ART?</article-title><source>AIDS</source><year>2017</year><month>11</month><volume>31</volume><issue>17</issue><fpage>2387</fpage><lpage>2391</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001629</pub-id><pub-id pub-id-type="medline">28857824</pub-id></nlm-citation></ref><ref id="ref12"><label>12</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>IA</given-names> </name><name name-style="western"><surname>Levine</surname><given-names>M</given-names> </name><name name-style="western"><surname>McGrath</surname><given-names>CJ</given-names> </name><etal/></person-group><article-title>Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: a cohort study in Kenya</article-title><source>EClinicalMedicine</source><year>2020</year><month>01</month><volume>18</volume><fpage>100239</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2019.100239</pub-id><pub-id pub-id-type="medline">31956856</pub-id></nlm-citation></ref><ref id="ref13"><label>13</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pham</surname><given-names>QD</given-names> </name><name name-style="western"><surname>Wilson</surname><given-names>DP</given-names> </name><name name-style="western"><surname>Law</surname><given-names>MG</given-names> </name><name name-style="western"><surname>Kelleher</surname><given-names>AD</given-names> </name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names> </name></person-group><article-title>Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis</article-title><source>AIDS</source><year>2014</year><month>11</month><day>28</day><volume>28</volume><issue>18</issue><fpage>2751</fpage><lpage>2762</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000494</pub-id><pub-id pub-id-type="medline">25493601</pub-id></nlm-citation></ref><ref id="ref14"><label>14</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names> </name><name name-style="western"><surname>Xu</surname><given-names>K</given-names> </name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Combining molecular network analysis and field epidemiology to quantify local HIV transmission and highlight ongoing epidemics</article-title><source>Int J Infect Dis</source><year>2023</year><month>03</month><volume>128</volume><fpage>187</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2022.12.033</pub-id><pub-id pub-id-type="medline">36587840</pub-id></nlm-citation></ref><ref id="ref15"><label>15</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paraskevis</surname><given-names>D</given-names> </name><name name-style="western"><surname>Beloukas</surname><given-names>A</given-names> </name><name name-style="western"><surname>Stasinos</surname><given-names>K</given-names> </name><etal/></person-group><article-title>HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors</article-title><source>BMC Med</source><year>2019</year><month>01</month><day>8</day><volume>17</volume><issue>1</issue><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s12916-018-1241-1</pub-id><pub-id pub-id-type="medline">30616632</pub-id></nlm-citation></ref><ref id="ref16"><label>16</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kassaye</surname><given-names>SG</given-names> </name><name name-style="western"><surname>Grossman</surname><given-names>Z</given-names> </name><name name-style="western"><surname>Vengurlekar</surname><given-names>P</given-names> </name><etal/></person-group><article-title>Insights into HIV-1 transmission dynamics using routinely collected data in the Mid-Atlantic United States</article-title><source>Viruses</source><year>2022</year><month>12</month><day>25</day><volume>15</volume><issue>1</issue><fpage>68</fpage><pub-id pub-id-type="doi">10.3390/v15010068</pub-id><pub-id pub-id-type="medline">36680108</pub-id></nlm-citation></ref><ref id="ref17"><label>17</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>X</given-names> </name><name name-style="western"><surname>Ma</surname><given-names>J</given-names> </name><name name-style="western"><surname>He</surname><given-names>Q</given-names> </name><etal/></person-group><article-title>HIV molecular transmission networks among students in Guangxi: unraveling the dynamics of student-driven HIV epidemic</article-title><source>Emerg Microbes Infect</source><year>2025</year><month>12</month><volume>14</volume><issue>1</issue><fpage>2459142</fpage><pub-id pub-id-type="doi">10.1080/22221751.2025.2459142</pub-id><pub-id pub-id-type="medline">39869005</pub-id></nlm-citation></ref><ref id="ref18"><label>18</label><nlm-citation citation-type="web"><article-title>HIV drug resistance report 2021</article-title><source>World Health Organization</source><year>2021</year><access-date>2025-01-21</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789240038608">https://www.who.int/publications/i/item/9789240038608</ext-link></comment></nlm-citation></ref><ref id="ref19"><label>19</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H</given-names> </name><name name-style="western"><surname>Hao</surname><given-names>J</given-names> </name><name name-style="western"><surname>Hu</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Pretreatment HIV drug resistance and the molecular transmission network among HIV-Positive individuals in China in 2022: multicenter observational study</article-title><source>JMIR Public Health Surveill</source><year>2023</year><month>11</month><day>17</day><volume>9</volume><fpage>e50894</fpage><pub-id pub-id-type="doi">10.2196/50894</pub-id><pub-id pub-id-type="medline">37976080</pub-id></nlm-citation></ref><ref id="ref20"><label>20</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuo</surname><given-names>L</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>K</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>H</given-names> </name><etal/></person-group><article-title>Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001-2017)</article-title><source>EClinicalMedicine</source><year>2020</year><month>01</month><volume>18</volume><fpage>100238</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2019.100238</pub-id><pub-id pub-id-type="medline">31922125</pub-id></nlm-citation></ref><ref id="ref21"><label>21</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>D</given-names> </name><name name-style="western"><surname>Hong</surname><given-names>Z</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names> </name><etal/></person-group><article-title>Analysis of genotype resistance and HIV-1 transmission risk in HIV-1-infected men who have sex with men in Guiyang, China</article-title><source>Immun Inflamm Dis</source><year>2024</year><month>11</month><volume>12</volume><issue>11</issue><fpage>e70029</fpage><pub-id pub-id-type="doi">10.1002/iid3.70029</pub-id><pub-id pub-id-type="medline">39552198</pub-id></nlm-citation></ref><ref id="ref22"><label>22</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>T</given-names> </name><name name-style="western"><surname>Bai</surname><given-names>C</given-names> </name><name name-style="western"><surname>Lu</surname><given-names>R</given-names> </name><etal/></person-group><article-title>HIV-1 molecular transmission network and drug resistance in Chongqing, China, among men who have sex with men (2018-2021)</article-title><source>Virol J</source><year>2023</year><month>07</month><day>13</day><volume>20</volume><issue>1</issue><fpage>147</fpage><pub-id pub-id-type="doi">10.1186/s12985-023-02112-0</pub-id><pub-id pub-id-type="medline">37443039</pub-id></nlm-citation></ref><ref id="ref23"><label>23</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Li</surname><given-names>H</given-names> </name><name name-style="western"><surname>Bai</surname><given-names>B</given-names> </name><etal/></person-group><article-title>Characterization of sexually acquired HIV-1 transmission networks and genetic variation in northern frontier China, 2021&#x2013;2024</article-title><source>Front Public Health</source><year>2026</year><month>06</month><volume>14</volume><fpage>1791010</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2026.1791010</pub-id></nlm-citation></ref><ref id="ref24"><label>24</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Han</surname><given-names>L</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names> </name><etal/></person-group><article-title>Establishment and application of a method of tagged-amplicon deep sequencing for low-abundance drug resistance in HIV-1</article-title><source>Front Microbiol</source><year>2022</year><volume>13</volume><fpage>895227</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2022.895227</pub-id></nlm-citation></ref><ref id="ref25"><label>25</label><nlm-citation citation-type="web"><source>WHO resistance quality control tool (WHO HIVDR QC tool) WHO/HIV ResNet HIV Drug Resistance Quality Control Tool</source><access-date>2025-01-21</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://sequenceqc-dev.bccfe.ca/who_qc">https://sequenceqc-dev.bccfe.ca/who_qc</ext-link></comment></nlm-citation></ref><ref id="ref26"><label>26</label><nlm-citation citation-type="web"><source>COMET HIV-1 homepage COMET HIV-1</source><access-date>2025-01-21</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://comet.lih.lu/index.php?cat=hiv1">https://comet.lih.lu/index.php?cat=hiv1</ext-link></comment></nlm-citation></ref><ref id="ref27"><label>27</label><nlm-citation citation-type="web"><person-group person-group-type="author"><collab>RIP</collab></person-group><source>HIV Sequence Database</source><access-date>2025-01-21</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/sequence/RIP/RIP.html">https://www.hiv.lanl.gov/content/sequence/RIP/RIP.html</ext-link></comment></nlm-citation></ref><ref id="ref28"><label>28</label><nlm-citation citation-type="web"><person-group person-group-type="author"><collab>JpHMM</collab></person-group><source>HIV Sequence Database</source><access-date>2025-01-21</access-date><comment><ext-link ext-link-type="uri" xlink:href="http://jphmm.gobics.de/">http://jphmm.gobics.de/</ext-link></comment></nlm-citation></ref><ref id="ref29"><label>29</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>MEJ</given-names> </name></person-group><article-title>Assortative mixing in networks</article-title><source>Phys Rev Lett</source><year>2002</year><month>11</month><day>11</day><volume>89</volume><issue>20</issue><fpage>208701</fpage><pub-id pub-id-type="doi">10.1103/PhysRevLett.89.208701</pub-id><pub-id pub-id-type="medline">12443515</pub-id></nlm-citation></ref><ref id="ref30"><label>30</label><nlm-citation citation-type="web"><source>HIV drug resistance database homepage Stanford University HIV Drug Resistance Database</source><access-date>2026-04-05</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://hivdb.stanford.edu/">https://hivdb.stanford.edu/</ext-link></comment></nlm-citation></ref><ref id="ref31"><label>31</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trebelcock</surname><given-names>WL</given-names> </name><name name-style="western"><surname>Lama</surname><given-names>JR</given-names> </name><name name-style="western"><surname>Duerr</surname><given-names>A</given-names> </name><etal/></person-group><article-title>HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru</article-title><source>J Intern AIDS Soc</source><year>2019</year><month>11</month><volume>22</volume><issue>11</issue><comment><ext-link ext-link-type="uri" xlink:href="https://onlinelibrary.wiley.com/toc/17582652/22/11">https://onlinelibrary.wiley.com/toc/17582652/22/11</ext-link></comment><pub-id pub-id-type="doi">10.1002/jia2.25411</pub-id></nlm-citation></ref><ref id="ref32"><label>32</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mwaniki</surname><given-names>SW</given-names> </name><name name-style="western"><surname>Kaberia</surname><given-names>PM</given-names> </name><name name-style="western"><surname>Mugo</surname><given-names>PM</given-names> </name><name name-style="western"><surname>Palanee-Phillips</surname><given-names>T</given-names> </name></person-group><article-title>HIV prevalence and associated risk factors among young tertiary student men who have sex with men (MSM) in Nairobi, Kenya: a respondent-driven sampling survey</article-title><source>AIDS Res Ther</source><year>2023</year><month>02</month><day>6</day><volume>20</volume><issue>1</issue><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s12981-023-00502-6</pub-id><pub-id pub-id-type="medline">36747178</pub-id></nlm-citation></ref><ref id="ref33"><label>33</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>BC</given-names> </name><name name-style="western"><surname>Fan</surname><given-names>MG</given-names> </name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Yang</surname><given-names>H</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>J</given-names> </name><name name-style="western"><surname>Yang</surname><given-names>J</given-names> </name></person-group><article-title>Epidemiological characteristics of HIV/AIDS among youths aged 15-24 years in Inner Mongolia Autonomous Region from 2018 to 2022</article-title><source>J Med Pest Control Apr</source><issue>S2</issue><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.11986/j.issn.1673-873X.2024.S2.04</pub-id></nlm-citation></ref><ref id="ref34"><label>34</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Takebe</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Wei</surname><given-names>H</given-names> </name><etal/></person-group><article-title>Geographic origin and evolutionary history of China&#x2019;s two predominant HIV-1 circulating recombinant forms, CRF07_BC and CRF08_BC</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><issue>1</issue><fpage>19279</fpage><pub-id pub-id-type="doi">10.1038/srep19279</pub-id></nlm-citation></ref><ref id="ref35"><label>35</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gan</surname><given-names>M</given-names> </name><name name-style="western"><surname>Zheng</surname><given-names>S</given-names> </name><name name-style="western"><surname>Hao</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Spatiotemporal Patterns of CRF07_BC in China: A Population-Based Study of the HIV Strain With the Highest Infection Rates</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>824178</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.824178</pub-id><pub-id pub-id-type="medline">35237270</pub-id></nlm-citation></ref><ref id="ref36"><label>36</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>H</given-names> </name><name name-style="western"><surname>Wu</surname><given-names>J</given-names> </name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>N</given-names> </name></person-group><article-title>Distribution of HIV-1 genotypes in China: a systematic review</article-title><source>Zhonghua Liu Xing Bing Xue Za Zhi</source><year>2014</year><month>10</month><volume>35</volume><issue>10</issue><fpage>1164</fpage><lpage>1168</lpage><pub-id pub-id-type="medline">25567027</pub-id></nlm-citation></ref><ref id="ref37"><label>37</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names> </name><name name-style="western"><surname>Li</surname><given-names>W</given-names> </name><name name-style="western"><surname>Zhong</surname><given-names>P</given-names> </name><etal/></person-group><article-title>Nationwide Trends in Molecular Epidemiology of HIV-1 in China</article-title><source>AIDS Res Hum Retroviruses</source><year>2016</year><month>09</month><volume>32</volume><issue>9</issue><fpage>851</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1089/AID.2016.0029</pub-id><pub-id pub-id-type="medline">27080587</pub-id></nlm-citation></ref><ref id="ref38"><label>38</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>WG</given-names> </name><name name-style="western"><surname>Yang</surname><given-names>XG</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>ZX</given-names> </name><etal/></person-group><article-title>Subtypes and transmission network analysis of HIV-1 in the MSM population in Baoding</article-title><source>Int J Virol Feb</source><year>2022</year><volume>29</volume><issue>1</issue><fpage>30</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.1673-4092.2022.01.006</pub-id></nlm-citation></ref><ref id="ref39"><label>39</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>QH</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>FX</given-names> </name><name name-style="western"><surname>Yue</surname><given-names>C</given-names> </name><etal/></person-group><article-title>Molecular Genotyping of HIV-1 Strains from Newly Infected Men Who Have Sex with Men in Harbin, China</article-title><source>AIDS Res Hum Retroviruses</source><year>2016</year><month>06</month><volume>32</volume><issue>6</issue><fpage>595</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1089/AID.2016.0028</pub-id><pub-id pub-id-type="medline">26892477</pub-id></nlm-citation></ref><ref id="ref40"><label>40</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>M</given-names> </name><name name-style="western"><surname>Tang</surname><given-names>J</given-names> </name><name name-style="western"><surname>Li</surname><given-names>J</given-names> </name><etal/></person-group><article-title>A novel HIV-1 circulating recombinant form (CRF168_0107) identified from men who have sex with men in Beijing, China</article-title><source>J Infect</source><year>2025</year><month>01</month><volume>90</volume><issue>1</issue><fpage>106368</fpage><pub-id pub-id-type="doi">10.1016/j.jinf.2024.106368</pub-id><pub-id pub-id-type="medline">39615845</pub-id></nlm-citation></ref><ref id="ref41"><label>41</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>C</given-names> </name><name name-style="western"><surname>Tan</surname><given-names>T</given-names> </name><name name-style="western"><surname>Li</surname><given-names>L</given-names> </name><etal/></person-group><article-title>Molecular network characteristics and drug resistance analysis of 392 newly reported MSM HIV/AIDS cases in Chongqing, China</article-title><source>Front Public Health</source><year>2024</year><volume>12</volume><fpage>1308784</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2024.1308784</pub-id><pub-id pub-id-type="medline">38903589</pub-id></nlm-citation></ref><ref id="ref42"><label>42</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>X</given-names> </name><name name-style="western"><surname>Xie</surname><given-names>B</given-names> </name><name name-style="western"><surname>He</surname><given-names>Q</given-names> </name><etal/></person-group><article-title>Distinct Rates and Transmission Patterns of Major HIV-1 Subtypes among Men who Have Sex with Men in Guangxi, China</article-title><source>Front Microbiol</source><year>2023</year><volume>14</volume><fpage>1339240</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2023.1339240</pub-id><pub-id pub-id-type="medline">38282731</pub-id></nlm-citation></ref><ref id="ref43"><label>43</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>SW</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>SF</given-names> </name><name name-style="western"><surname>Lin</surname><given-names>YT</given-names> </name><etal/></person-group><article-title>Patients infected with CRF07_BC have significantly lower viral loads than patients with HIV-1 subtype B: mechanism and impact on disease progression</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>12</issue><fpage>e114441</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0114441</pub-id><pub-id pub-id-type="medline">25502811</pub-id></nlm-citation></ref><ref id="ref44"><label>44</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Z</given-names> </name><name name-style="western"><surname>Yan</surname><given-names>H</given-names> </name><name name-style="western"><surname>Li</surname><given-names>Q</given-names> </name><etal/></person-group><article-title>Enhanced Transmissibility and Decreased Virulence of HIV-1 CRF07_BC May Explain Its Rapid Expansion in China</article-title><source>Microbiol Spectr</source><year>2022</year><month>08</month><day>31</day><volume>10</volume><issue>4</issue><fpage>e0014622</fpage><pub-id pub-id-type="doi">10.1128/spectrum.00146-22</pub-id><pub-id pub-id-type="medline">35727067</pub-id></nlm-citation></ref><ref id="ref45"><label>45</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romanescu</surname><given-names>RG</given-names> </name></person-group><article-title>Building a network with assortative mixing starting from preference functions, with application to the spread of epidemics</article-title><source>Front Phys</source><year>2024</year><volume>12</volume><fpage>1435767</fpage><pub-id pub-id-type="doi">10.3389/fphy.2024.1435767</pub-id></nlm-citation></ref><ref id="ref46"><label>46</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beyrer</surname><given-names>C</given-names> </name><name name-style="western"><surname>Baral</surname><given-names>SD</given-names> </name><name name-style="western"><surname>van Griensven</surname><given-names>F</given-names> </name><etal/></person-group><article-title>Global epidemiology of HIV infection in men who have sex with men</article-title><source>Lancet</source><year>2012</year><month>07</month><day>28</day><volume>380</volume><issue>9839</issue><fpage>367</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60821-6</pub-id><pub-id pub-id-type="medline">22819660</pub-id></nlm-citation></ref><ref id="ref47"><label>47</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names> </name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Mao</surname><given-names>L</given-names> </name><etal/></person-group><article-title>Targeting HIV Prevention Based on Molecular Epidemiology Among Deeply Sampled Subnetworks of Men Who Have Sex With Men</article-title><source>Clin Infect Dis</source><year>2015</year><month>11</month><day>1</day><volume>61</volume><issue>9</issue><fpage>1462</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1093/cid/civ526</pub-id><pub-id pub-id-type="medline">26129754</pub-id></nlm-citation></ref><ref id="ref48"><label>48</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>X</given-names> </name><name name-style="western"><surname>Liang</surname><given-names>S</given-names> </name><name name-style="western"><surname>Tang</surname><given-names>K</given-names> </name><etal/></person-group><article-title>Disparity of HIV-1 Pretreatment Drug Resistance in Men Who Have Sex With Men and the Heterosexual Population in Guangxi, China</article-title><source>Open Forum Infect Dis</source><year>2023</year><month>02</month><volume>10</volume><issue>2</issue><fpage>ofad016</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofad016</pub-id><pub-id pub-id-type="medline">36751650</pub-id></nlm-citation></ref><ref id="ref49"><label>49</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varghese</surname><given-names>V</given-names> </name><name name-style="western"><surname>Shahriar</surname><given-names>R</given-names> </name><name name-style="western"><surname>Rhee</surname><given-names>SY</given-names> </name><etal/></person-group><article-title>Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors</article-title><source>J Acquir Immune Defic Syndr</source><year>2009</year><month>11</month><day>1</day><volume>52</volume><issue>3</issue><fpage>309</fpage><lpage>315</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://19734799">19734799</ext-link></comment><pub-id pub-id-type="doi">10.1097/QAI.0b013e3181bca669</pub-id><pub-id pub-id-type="medline">19734799</pub-id></nlm-citation></ref><ref id="ref50"><label>50</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sluis-Cremer</surname><given-names>N</given-names> </name></person-group><article-title>The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors</article-title><source>Viruses</source><year>2014</year><month>07</month><day>31</day><volume>6</volume><issue>8</issue><fpage>2960</fpage><lpage>2973</lpage><pub-id pub-id-type="doi">10.3390/v6082960</pub-id><pub-id pub-id-type="medline">25089538</pub-id></nlm-citation></ref><ref id="ref51"><label>51</label><nlm-citation citation-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Updated recommendations on first-line and second-line antiretroviral regimens and postexposure prophylaxis and recommendations on early infant diagnosis of HIV</article-title><access-date>2026-04-05</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/WHO-CDS-HIV-18.51">https://www.who.int/publications/i/item/WHO-CDS-HIV-18.51</ext-link></comment></nlm-citation></ref><ref id="ref52"><label>52</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>HX</given-names> </name><name name-style="western"><surname>Cai</surname><given-names>L</given-names> </name><name name-style="western"><surname>Cai</surname><given-names>WP</given-names> </name></person-group><article-title>Expert Consensus on the Management of Antiretroviral Drug Resistance in HIV/AIDS Patients in China</article-title><source>Chinese Journal of AIDS &#x0026; STD</source><year>2025</year><volume>31</volume><issue>9</issue><fpage>1013</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.13419/j.cnki.aids.2025.09.17</pub-id></nlm-citation></ref><ref id="ref53"><label>53</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names> </name><name name-style="western"><surname>Mei</surname><given-names>J</given-names> </name><name name-style="western"><surname>Yu</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Characteristics of molecular epidemiology and transmitted drug resistance among newly diagnosed HIV-1 infections in Lishui, China from 2020 to 2023</article-title><source>Virol J</source><year>2025</year><month>04</month><day>19</day><volume>22</volume><issue>1</issue><fpage>111</fpage><pub-id pub-id-type="doi">10.1186/s12985-025-02734-6</pub-id><pub-id pub-id-type="medline">40253369</pub-id></nlm-citation></ref><ref id="ref54"><label>54</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>D</given-names> </name><name name-style="western"><surname>Hu</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Changes in HIV-1 Subtypes/Sub-Subtypes, and Transmitted Drug Resistance Among ART-Na&#x00EF;ve HIV-Infected Individuals - China, 2004-2022</article-title><source>China CDC Wkly</source><year>2023</year><month>07</month><day>28</day><volume>5</volume><issue>30</issue><fpage>664</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.46234/ccdcw2023.129</pub-id><pub-id pub-id-type="medline">37593123</pub-id></nlm-citation></ref><ref id="ref55"><label>55</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mungati</surname><given-names>M</given-names> </name><name name-style="western"><surname>Mhangara</surname><given-names>M</given-names> </name><name name-style="western"><surname>Gonese</surname><given-names>E</given-names> </name><etal/></person-group><article-title>Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008-2010</article-title><source>BMC Res Notes</source><year>2016</year><month>06</month><day>10</day><volume>9</volume><fpage>302</fpage><pub-id pub-id-type="doi">10.1186/s13104-016-2101-8</pub-id><pub-id pub-id-type="medline">27287672</pub-id></nlm-citation></ref><ref id="ref56"><label>56</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bissio</surname><given-names>E</given-names> </name><name name-style="western"><surname>Barb&#x00E1;s</surname><given-names>MG</given-names> </name><name name-style="western"><surname>Bouzas</surname><given-names>MB</given-names> </name><etal/></person-group><article-title>Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014-15</article-title><source>J Antimicrob Chemother</source><year>2017</year><month>02</month><volume>72</volume><issue>2</issue><fpage>504</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1093/jac/dkw445</pub-id><pub-id pub-id-type="medline">27789684</pub-id></nlm-citation></ref><ref id="ref57"><label>57</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T</given-names> </name><name name-style="western"><surname>Dou</surname><given-names>H</given-names> </name><name name-style="western"><surname>Ye</surname><given-names>H</given-names> </name><etal/></person-group><article-title>Transmitted drug resistance and molecular transmission network among treatment-naive HIV-1 patients in Wenzhou, China, 2020-2023</article-title><source>Virol J</source><year>2024</year><month>10</month><day>17</day><volume>21</volume><issue>1</issue><fpage>257</fpage><pub-id pub-id-type="doi">10.1186/s12985-024-02528-2</pub-id><pub-id pub-id-type="medline">39420358</pub-id></nlm-citation></ref><ref id="ref58"><label>58</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lanting</surname><given-names>VR</given-names> </name><name name-style="western"><surname>Oosterhof</surname><given-names>P</given-names> </name><name name-style="western"><surname>Ait Moha</surname><given-names>D</given-names> </name><etal/></person-group><article-title>Switching to Doravirine in cART-Experienced Patients: An Effective and Highly Tolerated Option With Substantial Cost Savings</article-title><source>J Acquir Immune Defic Syndr</source><year>2024</year><month>02</month><day>1</day><volume>95</volume><issue>2</issue><fpage>190</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000003337</pub-id><pub-id pub-id-type="medline">37963350</pub-id></nlm-citation></ref></ref-list><app-group><supplementary-material id="app1"><label>Multimedia Appendix 1</label><p>Participant flow diagram.</p><media xlink:href="publichealth_v12i1e82208_app1.pptx" xlink:title="PPTX File, 39 KB"/></supplementary-material></app-group></back></article>